

Antonio Galvano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9271771/antonio-galvano-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

1,151
citations

20
h-index

32
g-index

64
ext. papers

1,451
ext. citations

4.7
avg, IF

4.32
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 60 | Safety and effectiveness of gemcitabine for the treatment of classic Kaposi sarcoma without visceral involvement.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221086829 | 5.4 | |
| 59 | Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022 , 7, 100459 | 6.9 | 1 |
| 58 | The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103567 | 7 | 13 |
| 57 | Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103525 | 7 | 12 |
| 56 | Cancer of Exocrine Pancreas. <i>UNIPA Springer Series</i> , 2021 , 645-674 | 0.1 | |
| 55 | Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103282 | 8.2 | 1 |
| 54 | Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests (SEDRT) (CARG+CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e12510-e12510 | 2.2 | 0 |
| 53 | Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021 , 2, 173-196 | 0.4 | 10 |
| 52 | Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. <i>Frontiers in Oncology</i> , 2021 , 11, 750075 | 5.4 | 4 |
| 51 | Not all 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211049779 | 5.4 | 0 |
| 50 | The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18, | 4.6 | 5 |
| 49 | Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 319-326 | 5.4 | 8 |
| 48 | The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020 , 85, 101994 | 14.4 | 51 |
| 47 | Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020 , 12, | 6.6 | 8 |
| 46 | Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020 , 37, 1145-1155 | 4.1 | 52 |
| 45 | COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , 2020 , 10, 734 | 5.3 | 29 |
| 44 | Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16093-e16093 | 2.2 | 0 |

| | | | |
|----|---|------|----|
| 43 | Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252). <i>Journal of Bone Oncology</i> , 2020 , 22, 100295 | 4.5 | 1 |
| 42 | Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920942378 | 5.4 | 22 |
| 41 | Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer. <i>Anticancer Research</i> , 2020 , 40, 7083-7088 | 2.3 | 1 |
| 40 | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020 , 13, | 5.2 | 22 |
| 39 | How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11, | 6.6 | 2 |
| 38 | Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019 , 36, 2600-2617 | 4.1 | 52 |
| 37 | Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919874653 | 5.4 | 18 |
| 36 | An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 485-496 | 4.1 | 6 |
| 35 | Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919839928 | 5.4 | 29 |
| 34 | Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019 , 18, 100252 | 4.5 | 13 |
| 33 | How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 68-75 | 7 | 3 |
| 32 | Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019 , 2019, 5458717 | 4.5 | 8 |
| 31 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485 | 21.7 | 39 |
| 30 | Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 471-478 | 4.2 | 5 |
| 29 | Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. <i>International Journal of Cancer</i> , 2018 , 142, 1277-1284 | 7.5 | 55 |
| 28 | The use of SAME in chemotherapy-induced liver injury. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 70-77 | 7 | 14 |
| 27 | Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2018 , 9, 17906-17914 | 3.3 | 4 |
| 26 | Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer. <i>Oncotarget</i> , 2018 , 9, 20339-20350 | 3.3 | 5 |

| | | | |
|----|--|-----|-----|
| 25 | Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. <i>Oncotarget</i> , 2018 , 9, 31861-31876 | 3.3 | 4 |
| 24 | Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. <i>Current Cancer Drug Targets</i> , 2018 , 18, 697-705 | 2.8 | 23 |
| 23 | The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018 , 8, 13379 | 4.9 | 48 |
| 22 | Indications for Locoregional Tumor Therapies: CRC Liver Metastases 2018 , 83-106 | | |
| 21 | Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study. <i>Oncology</i> , 2017 , 92, 94-100 | 3.6 | 7 |
| 20 | The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 120, 227-233 | 7 | 12 |
| 19 | Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. <i>Oncotarget</i> , 2017 , 8, 37875-37883 | 3.3 | 11 |
| 18 | "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. <i>Oncotarget</i> , 2017 , 8, 23891-23904 | 3.3 | 17 |
| 17 | Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin. <i>Oncotarget</i> , 2017 , 8, 71924-71932 | 3.3 | 20 |
| 16 | Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 188-97 | 5.4 | 17 |
| 15 | Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 150-7 | 7 | 60 |
| 14 | Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. <i>Oncotarget</i> , 2016 , 7, 60712-60722 | 3.3 | 79 |
| 13 | PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016 , 7, 19738-47 | 3.3 | 106 |
| 12 | KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3565-3565 | 2.2 | |
| 11 | Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016 , 7, 47821-47830 | 3.3 | 28 |
| 10 | Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016 , 37, 7109-18 | 2.9 | 21 |
| 9 | The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 107, 20-32 | 7 | 24 |
| 8 | Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015 , 47, 324-30 | 3.3 | 30 |

| | | | |
|---|--|-----|----|
| 7 | Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 125-132 | 5.9 | 5 |
| 6 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 45-59 | 5.4 | 8 |
| 5 | Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2015 , 10, e0124587 | 3.7 | 24 |
| 4 | New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015 , 6, 24780-96 | 3.3 | 70 |
| 3 | Ramucirumab and its use in gastric cancer treatment. <i>Drugs of Today</i> , 2014 , 50, 613-21 | 2.5 | 2 |
| 2 | Monoclonal antibodies in gastrointestinal cancers. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 889-904 | 3.4 | 17 |
| 1 | Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations. <i>Oncology</i> , 2013 , 85, 306-11 | 3.6 | 14 |